Bio Path Holdings Stock Today
| BPTH Stock | USD 0.84 0.02 2.44% |
Performance3 of 100
| Odds Of DistressOver 84
|
Bio Path is trading at 0.84 as of the 30th of January 2025. This is a 2.44 percent increase since the beginning of the trading day. The stock's open price was 0.82. Bio Path has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 5.77 M outstanding shares of which 180.96 K shares are currently shorted by private and institutional investors with about 0.03 trading days to cover. More on Bio Path Holdings
Moving against Bio Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Bio Stock Highlights
Bio Path Holdings (BPTH) is traded on NASDAQ Exchange in USA. It is located in 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401 and employs 10 people. Bio Path is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.83 M. Bio Path Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 5.77 M outstanding shares of which 180.96 K shares are currently shorted by private and institutional investors with about 0.03 trading days to cover.
Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Bio Path Probability Of Bankruptcy
Ownership AllocationAlmost 98.92 percent of Bio Path outstanding shares are held by general public with 1.08 % by other corporate entities.
Check Bio Ownership Details
Bio Path Holdings Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bio Path market risk premium is the additional return an investor will receive from holding Bio Path long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0426 | |||
| Jensen Alpha | 0.4239 | |||
| Total Risk Alpha | (0.88) | |||
| Sortino Ratio | 0.0875 |
Bio Stock Against Markets
Bio Path Corporate Management
| Michael MBA | VP Operations | Profile | |
| Alan MacKenzie | Consultant | Profile | |
| Thomas Walker | Consultant | Profile | |
| MBA Ashizawa | Development Research | Profile | |
| Peter MBA | Chairman, CoFounder | Profile | |
| Jeffery MD | Consultant | Profile | |
| Victoria Rac | Regulatory Consultant | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.